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PURPOSE. The aim of the present study was the in vitro and in
vivo evaluation of a novel aqueous formulation based on
polymeric micelles for the topical delivery of cyclosporine A
for dry eye treatment.
METHODS. In vitro experiments were carried out on primary
rabbit corneal cells, which were characterized by immunocy-
tochemistry using fluorescein-labeled lectin I/isolectin B4 for
the endothelial cells and mouse monoclonal antibody to
cytokeratin 3þ12 for the epithelial ones. Living cells were
incubated for 1 hour or 24 hours with a fluorescently labeled
micelle formulation and analyzed by fluorescence microscopy.
In vivo evaluations were done by Schirmer test, osmolarity
measurement, CyA kinetics in tears, and CyA ocular distribu-
tion after topical instillation. A 0.05% CyA micelle formulation
was compared to a marketed emulsion (Restasis).
RESULTS. The in vitro experiments showed the internalization of
micelles in the living cells. The Schirmer test and osmolarity
measurements demonstrated that micelles did not alter the
ocular surface properties. The evaluation of the tear fluid gave
similar CyA kinetics values: AUC ¼ 2339 6 1032 min*lg/mL
and 2321 6 881.63; Cmax¼ 478 6 111 lg/mL and 451 6 74;
half-life ¼ 36 6 9 min and 28 6 9 for the micelle formulation
and Restasis, respectively. The ocular distribution investigation
revealed that the novel formulation delivered 1540 6 400 ng
CyA/g tissue to the cornea.
CONCLUSIONS. The micelle formulation delivered active CyA into
the cornea without evident negative influence on the ocular
surface properties. This formulation could be applied for
immune-related ocular surface diseases. (Invest Ophthalmol
Vis Sci. 2012;53:2292–2299) DOI:10.1167/iovs.11-8829
Dry eye is a multifactorial disease, with two majorrecognized forms: one is characterized by a reduction of
tear production, and the other is characterized by tear
hyperosmolarity, mainly due to excessive evaporative water
loss.1,2 These two components of dry eye engender inflamma-
tion and ocular surface irritation. Thus, the goals for the
treatment of this disease are to improve the patient’s ocular
comfort and to return the ocular surface and tear composition
to their basal and healthy states. Two main therapeutic
approaches are used in the clinic: instillation of artificial tears
for tear supplementation and stimulation and instillation of
anti-inflammatory drugs to reduce ocular surface inflamma-
tion.3 Inflammation can be reduced by the use of corticoste-
roids, tetracyclines or cyclosporin A. For CyA, the mechanism
of action of how tear production is increased is not totally
clear, but it seems to be related to its immuno-modulatory
activity, which decreases the local inflammation.3 CyA is a
neutral, cyclic undecapeptide with many pharmacological
activities: suppression of T-cell–mediated responses, inhibition
of chronic inflammatory reactions, fungicidal activity, and anti-
hepatitis C virus activity.4 This drug has been extensively used
to suppress the alloimmune response after solid organ
transplantation since the 1970s. Other applications of CyA
are the treatment of ophthalmic diseases such as dry eye
syndrome and autoimmune uveitis, and the prevention of
corneal graft rejection.5 CyA has also been investigated for
treating several eye infections, such as posterior blepharitis,6
atopic keratoconjunctivitis,7 and herpetic stromal keratitis.8
For many of these diseases, high systemic concentrations of
CyA have to be administered to reach therapeutic ocular drug
levels (50–300 ng CyA/g tissue),
9 resulting in serious side effects,
such as nephrotoxicity and hypertension.4 Hence, a topical
and local CyA administration would be favorable to directly
target the disease site, especially for the ocular surface
treatment in dry eye. However, due to its high hydrophobicity
(log P octanol/water¼ 8.2) and its low water solubility at 258C
(0.012 mg/mL),10 CyA is difficult to formulate into a topical
aqueous solution at an effective concentration. Despite many
research efforts, only one emulsion for dry eye treatment has
reached the US market: Restasis (Allergan, Irvine, CA). This
formulation reduces the disease symptoms by decreasing
activated lymphocytes.11 However, it has drawbacks, such as
burning and stinging sensations.12 To decrease local side
effects and to enhance the patient’s comfort, CyA colloidal
drug delivery systems are an interesting option for formula-
tions to enable them to overcome ocular barriers.13–16
The present work is focused on a novel topical micelle
formulation based on methoxy poly(ethylene) glycol (MPEG)-
hexyl-substituted poly(lactides) (hexPLA) to treat immune-
related ocular diseases and, in particular, dry eye syndrome.
The formulation presented here has already shown excellent in
vitro and in vivo ocular biocompatibility and efficiency in CyA
solubilization.10,16 Here, in vitro and in vivo tests were
performed to evaluate the suitability of this micelle formulation
for dry eye treatment. The capacity of MPEG-hexPLA micelles
to penetrate into primary corneal cells was investigated. The
uptake into corneal cells is essential for CyA accumulation and
action in the cornea, from which CyA could be released over
time. Because there is no satisfactory animal model available
that can reproduce globally the complexity of dry eye
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disease,17 the novel formulation was investigated in vivo in
several tests to determine the formulation’s impact on several
ocular surface properties that are relevant to dry eye. The
Schirmer test is an evaluation of the basal and reflex tear
secretion, and the isotonicity test is an indication of the
lachrymal fluid modifications.18 Both are currently used in the
diagnosis of dry eye, and here they were used to evaluate
possible modifications of the ocular surface by the micelle
formulation. The pharmacokinetics of tear fluid was studied to
determine the available CyA concentration in the precorneal
surface after a single instillation. The quantitative corneal
uptake after topical administration was studied in vivo in rat
eyes. For all these in vivo evaluations, a 0.05% CyA/MPEG-
hexPLA micelle formulation was compared with the marketed
formulation Restasis at the same CyA concentration.
MATERIALS AND METHODS
Materials
MPEG (molecular weight ¼ 2000 g/mol) was purchased from Union
Carbide Corporation (Texas City, TX). a-Hydroxyoctanoic acid, 3,6-
dihexyl-1,4-dioxane-2,5-dione (dihexyl-substituted lactide, hexLA), and
MPEG-hexPLA were synthesized as described previously.19,20 The
fluorescent Nile Red–labeled MPEG-hexPLA was synthesized in the
laboratory (Trubtsyn G. et al. 2011, submitted).
The following products were purchased from these companies:
Sigma-Aldrich (Munich, Germany): stannous 2-ethylhexanoate,
sucrose, bovine serum albumin fraction V, hydrocortisone and glycerol;
Biotium (Hayward, CA): 3,3-dioctadecyloxacarbocyanine perchlorate
(DiOC18(3)); Invitrogen (Carlsbad, CA): serum-free keratinocyte
medium, pituitary extract, recombinant epidermal growth factor,
0.05% trypsin-EDTA; Vector Laboratories (Burlingame, CA): fluoresce-
in-labeled lectin I/isolectin B4; Abcam (Cambridge, MA): mouse
monoclonal antibody to cytokeratin 3þ12; Roche (Basel, Switzerland):
fibronectin; Cellial Technologies (Lens, France): rat tail collagen;
Novartis (Basel, Switzerland): 0.4% oxybuprocaine eye drops; The´a
(Cleremont-Ferrand, France): dina strip Schirmer plus; Allergan (Irvine,
CA): Restasis; Dynapharm Distribution (Geneva Switzerland): cyclo-
sporin A; Fluka (Munich, Germany): analytical grade acetone, ethanol;
VWR (Fontenay-sous-Bois, France): methanol for HPLC; Biosolve
(Valkenswaard, The Netherlands): methanol for UPLC/MS MilliQ water
was used in each experiment.
Tear osmolarity test cards were a kind gift from Tear Lab
Corporation (San Diego, CA).
Methods
For the precorneal kinetics evaluation, Schirmer test, and isotonicity
test, New Zealand rabbits, female, weighing 4–5 kg, were used. Before
starting the experiments, a visual evaluation of any corneal surface
damage as well as fluorescein tests were performed to ensure the non-
obstruction of the naso-lachrymal drainage system. The experimental
protocol was approved by the Canton of Geneva’s Local Ethics
Committee for Animal Experimentation (1020/325/1).
For the ocular distribution experiment, 12 female, 8-week-old, 150–
200 g Lewis rats were used. The experimental protocol was in
accordance with the European Committee Directives (authorization
numbers: A 75-06-12 and 75-580). All animals were treated in
accordance with the ARVO Statement for the Use of Animals in
Ophthalmic and Vision Research.21
Preparation and Characterization of the Polymeric
Micelle Formulation
Micelle formulations were prepared as described previously by a
solvent evaporation method.16,22 Briefly, 40 mg of MPEG-hexPLA
copolymer and 8.8 mg of CyA were dissolved in 2.0 mL acetone. This
organic phase was added dropwise under probe sonication (Digital
Sonifier 450, Branson, Danbury, CT) to 4.0 mL of 10 mM phosphate
buffer with 10% sucrose. The acetone was then evaporated under
vacuum. The obtained micelle formulation had a final copolymer
concentration of 10 mg/mL. After CyA quantification, the formulation
was diluted with the isotonic 10 mM phosphate buffer solution to
obtain a final CyA concentration of 0.05%. The fluorescent micelle
formulation was prepared with the same method and had a final
copolymer concentration of 20 mg/mL, with a 12:88 weight ratio
between the Nile Red–labeled MPEG-hexPLA and MPEG-hexPLA, and
3% w/w DiO was loaded inside. DiO was used here as a model drug for
CyA. The formulations were characterized in terms of size, morphol-
ogy, and drug loading using dynamic laser scattering (Zetasizer HS
3000, Malvern Instruments, Malvern, UK), transmission electron
microscopy (FEI Tecnai G2 Sphera, Hillsboro, OR), and high-pressure
liquid chromatography (Waters, Montreux-Chailly, Switzerland), re-
spectively, as described in previous studies.16,22 All formulations were
filtered under sterile conditions before use.
In Vitro Cellular Test
Two different cell cultures were carried out: (1) Rabbit primary corneal
cells were isolated from the corneas of two animals by trypsinization
of both sides (epithelium and endothelium). The harvested cells were
seeded into a 60-mm tissue culture dish coated with 0.01 mg/mL
fibronectin, 0.03 mg/mL rat tail collagen, and 0.01 mg/mL bovine
serum albumin type V. The cells were cultured with keratinocyte
serum-free medium supplemented with 1% penicillin/streptomycin,
500 ng/mL bovine pituitary extract, 5 ng/mL recombinant epidermal
growth factor, and 500 ng/mL hydrocortisone, as recommended by the
supplier, in a humidified atmosphere at 378C with 5% CO2.
(2) Whole corneas were kept in culture under the same conditions,
and cells from the corneas were able to migrate out of the tissue to
form a mixed culture of corneal cells. At maximum two passages were
performed for each culture, and cells were used after approximately 2
weeks of culture.
Identification of Corneal Cells by Immunocytochemistry. To
characterize these corneal cells, immunocytochemistry was per-
formed using an anti-cytokeratin 3þ12 antibody and fluorescein-
labeled lectin I/isolectin B4, which specifically recognized epithelial
and endothelial cells, respectively. For this purpose, cells were first
fixed with cold absolute ethanol at -208C for 10 minutes and then
permeabilized by 0.1% Triton X100-PBS solution at room temperature
for 10 minutes. Cells were subsequently incubated with 3% BSA-PBS
for 30 minutes prior to incubation at 48C with the monoclonal anti-
cytokeratin 3þ12 antibody (2Q1040) in a PBS solution containing 3%
BSA overnight. Finally, the cells were incubated at room temperature
for 1 hour with the appropriate combination of fluorescently labeled
secondary antibody and/or with fluorescein lectin I/isolectin B4 in
PBS with 3% BSA. Each step was followed by washes with PBS. For all
stainings, cells were finally mounted on glass microscopic slides using
Glycergel mounting medium (Dako, Glostrup, Denmark). Slides were
then observed with an AXIO Imager Z1m fluorescence microscope
(Zeiss, Feldbach, Switzerland). Images were taken using a digital
Axiocam MRm camera (Zeiss). A magnification of 63X was used for all
observations.
Micelle Uptake by Primary Rabbit Corneal Cells. To evaluate
cellular uptake, a fluorescent micelle formulation with a copolymer
concentration of 3 mg/mL was used. Culture medium was removed,
and the cells were incubated with the micelle solution diluted 1/6 in
culture medium and then incubated at 378C in a humidified
atmosphere with 5% CO2 for 1 hour or 24 hours. After the desired
incubation time, the micelle solution was removed, and cells were
washed twice with culture medium and incubated with Hoechst
solution for 5 minutes to stain the nuclei. Living cells were then
immediately observed by an integrated system for advanced widefield
fluorescence imaging and analysis (AF6000, Leica, Germany) and, for
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the cells incubated 24 hours, also by confocal microscopy with a 510
Meta microscope (Zeiss).
CyA Kinetics in Lachrymal Fluid after Topical
Instillation
For kinetics experiments, six rabbits were treated with the CyA/MPEG-
hexPLA micelle formulation and six others with Restasis for
comparison. Twenty-five microliters of the formulation was instilled
in the right eye of each rabbit with a calibrated micropipette
(Assipettor-digital, Assistent, Sondheim, Germany). Two microliters of
tear fluid was withdrawn at each time point using a 2-lL microcap
capillary (Drummond Scientific Co., Broomall, PA). The time points
were 0, 1, 3, 6, 8, 10, 12, 14, 16, 18, 20, 30, 60, 90, 120, 150, and 180
minutes after instillation. Each 2-lL aliquot was diluted in a vial
containing 50 lL of methanol and 100 ppb of deuterated CyA as an
internal standard. The vials were vortexed and analyzed by UPLC/
MS_MS.23 The CyA half-life, maximal concentration, and area under the
curve were calculated for both formulations with WinNonlin 5.2
version software.
Evaluation of the Basal Tear Production after
Topical Instillation
The basal tear production was measured by a Schirmer test carried out
on six rabbits for each formulation, the CyA/MPEG-hexPLA micelle
formulation and Restasis. A single instillation of 25 lL was done in the
right eye, and the test was performed before and after 1, 2, 4, 6, 24, and
48 hours of instillation. Topical anesthesia was performed by
instillation of 1 drop of 0.4% oxybuprocaine solution 5 minutes before
the insertion of the Schirmer test strip in the cul-de-sac. The time of the
test was 5 minutes. The height of the Schirmer test strip wetted by the
tears was measured in millimeters and plotted versus time.
Evaluation of Tear Osmolarity after Topical
Instillation
Tear osmolarity was measured using a TearLab Osmolarity System
(TearLab Corporation, San Diego, CA) equipped with osmolarity test
cards. The instrument is designed to withdraw a volume of 50 nL of
tears. The osmolarity was measured before and after 30, 60, and 120
minutes instillation of a 25-lL formulation containing 0.05% CyA/MPEG-
hexPLA or Restasis. Three animals were used for each formulation.
CyA Ocular Distribution after Topical Instillation
The ocular distribution of the CyA micelle formulation and Restasis was
evaluated in six rats per formulation. Two instillations per day were
performed for 5 days. After sacrifice with CO2, the cornea, iris-ciliary
body, aqueous humor, and vitreous were recuperated. The blood was
recovered directly from the heart with a syringe, collected in a 2-mL vial,
and stored at 48C for 30 minutes before centrifugation at 9000g for 15
minutes. The obtained serum was kept at -808C until further analyses.
The cornea, iris-ciliary body, aqueous humor, and vitreous of both eyes
(treated and contralateral) were stored under the same conditions in
protected vials. For the analyses, the tissues were thawed at room
temperature, weighed, manually grinded, and treated as follows: 100 lL
of serum was diluted with 400 lL of methanol containing 100 ppb of
deuterated CyA as internal standard; and 200 lL of methanol containing
internal standard was added to the cornea, aqueous humor, iris-ciliary
body, and vitreous samples. After stirring for 12 hours, the samples were
centrifuged and 150 lL of the supernatant was transferred in UPLC vials.
The CyA was quantified by UPLC/MS_MS.
Statistics
For all comparisons, the Mann-Whitney test was used (unpaired samples).
Samples were significantly different from each other when P < 0.05.
RESULTS
Preparation and Characterization of Polymeric
Micelles
The CyA micelle formulation used for all the studies had the
following characteristics: pH 7.4 6 0.1, isotonicity 318 6 1
mmol/kg, and CyA concentration 0.50 6 0.01 mg/mL, with a
copolymer concentration of 3 mg/mL. The micelles had a
hydrodynamic diameter of 35 6 1 nm, with a polydispersity
index of 0.200 6 0.013. The fluorescent micelle formulation
had the same pH and isotonicity as the CyA formulation and a
micelle size of 32 6 1 nm with a PI of 0.453 6 0.044.
In Vitro Cellular Tests
Immunocytochemistry showed that different cell types were
present when the corneas were cultured. After incubation
with the anti-cytokeratin 3þ12 antibody and with fluorescein
lectin I/isolectin B4, epithelial cells were only stained by the
anti-cytokeratin 3 þ 12 antibody (Fig. 1, left side), and
endothelial cells were stained only by the fluorescein lectin
I/isolectin B4 (Fig. 1, right side).
The epithelial and endothelial corneal cells obtained by
cornea culture were used for cellular uptake experiments. The
micelle formulation was prepared with a Nile red–labeled
copolymer and loaded with DiO, which fluoresces green.
Intact micelles carrying the model drug were visible by the
yellow fluorescence due to the colocalization of red and green
fluorescence. When the micelle released the model drug DiO,
green fluorescence was observed.
After 1 hour of incubation with the fluorescent micelle
formulation, yellow spots were present in the cells (Figs. 1a,
1b). Thus, micelles carrying the model drug DiO were able to
interact with the cellular membrane and to penetrate into the
cells. After 24 hours of incubation, a yellow fluorescence was
still detectable, but at a lower intensity (Figs. 1c, 1d). In
addition, green fluorescence was visible, suggesting that the
micelles started to release the model drug inside the cells.
The observation of cells by confocal microscopy after
incubation with the fluorescent micelle formulation for 24
hours showed the presence of green, red, and yellow
fluorescence at the same level as the blue fluorescence
(nuclei), meaning that micelles were able to penetrate into
the corneal cells (Fig. 3).
CyA Kinetics in Lachrymal Fluid after Topical
Instillation
The precorneal kinetics was evaluated in rabbit eyes after one
instillation of the CyA micelle formulation or Restasis. The
FIGURE 1. Corneal cells stained with monoclonal anti-cytokeratin
3þ12 antibody (red) and endothelial cells stained with fluorescein
lectin I/isolectin B4 (green).
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obtained CyA concentrations in the lachrymal fluid are
presented in Fig. 4. For both formulations, the elimination
profile of CyA from the tears after topical instillation was
biphasic (Fig. 4a), with a rapid elimination of the drug within
the first 20 minutes (Fig. 4b) and slower thereafter (Fig. 4c). No
significant difference in kinetics was found between the two
formulations.
The AUC, Cmax, and half-life are reported in Table 1. All
three values were higher for the micelle formulation, although
they were not significantly different from those of Restasis.
Evaluation of Basal Tear Production after Topical
Instillation
The Schirmer test was performed in rabbit eyes to evaluate
the tear secretion after topical instillation of 25 lL of either
formulation. The initial mean values (time zero) were
between 9.8 mm and 10.6 mm for all animals. Even though
no significant difference was found, it was noticed for the
rabbits treated with the micelle formulation that the tear
production was always higher than the baseline, except after
4 hours, when it was equal to the baseline. For the eyes
treated with Restasis, more fluctuations were visible. For both
formulations, the value after 48 hours was similar to the
baseline value.
Evaluation of Tear Osmolarity after Topical
Instillation
The initial isotonicity values of tears were 347 mOsm/kg for
eyes treated with the micelle formulation and 366 mOsm/kg
for eyes treated with Restasis. At all time points studied, no
significant variations from the initial mean values were
observed for both formulations.
CyA Ocular Distribution Study after Topical
Instillation
The ocular distribution of CyA was examined in rat eyes after
topical instillation of the CyA micelle formulation or Restasis
twice per day for 5 days. The mean CyA concentration in the
corneas of the animals treated with the CyA/MPEG-hexPLA
micelle formulation was 1540 6 400 ng CyA/g tissue. The CyA
concentrations in aqueous humor and the iris-ciliary body were
below 2 ng/mL, which was the limit of quantification of the
analytical method used. Only in two eyes of the six treated
with the micelle formulation was the CyA concentration in the
vitreous higher than 2 ng/mL.
In the eyes treated with Restasis, the CyA concentration
was higher than 2 ng/mL only in the cornea and vitreous of one
out of six rats. In all other ocular tissues, the CyA
concentration was below the LOQ.
In all blood samples, the CyA concentration was below the
LOQ of 2 ng/mL.
DISCUSSION
The bioavailability of drugs is reduced by two principal factors:
instability in the biological environment and limited transport
across biological membranes.24 A carrier that can protect the
drug, rapidly pass through epithelia, and execute a sustained
drug release after administration is an attractive solution to
improve drug bioavailability. Nano-sized colloidal systems have
both abilities. In fact, the particle size is one key factor for
passing through biological membranes, and nano-sized parti-
cles penetrate the corneal layers through a transcellular
pathway.25 In addition, some colloidal systems have shown
improved drug protection in physiological conditions.26,27 In
the last decade, many colloidal systems have been developed
for ophthalmic application.28 For example, liposomes and
PLGA (poly(lactic-co-glycolic acid)) nanoparticles were able to
prolong the retention at the corneal site for the hydrophobic
drugs indoxole29 and sparfloxacin,30 respectively. Solid lipid
nanoparticles, based on glyceryl dibehenate as the lipid phase
and poly(ethylene)-poly(propylene) glycol and polysorbates as
the aqueous phase, have been proposed as a topical ocular
carrier for CyA.31 This system was efficient in solubilizing CyA
and in increasing the corneal permeation in ex vivo studies on
pig corneas compared to a 0.05% CyA suspension used as a
reference. Among the reported colloidal systems, polymeric
micelles have interesting and promising characteristics for
ophthalmic applications, such as their simple preparation and
nano size, the transparency and the stability of their
formulations, their efficiency in drug loading, and localized
drug release.
In this study, polymeric micelles were used as colloidal
carriers for ocular delivery of CyA after topical instillation for
dry eye treatment. A commercial emulsion, Restasis, was used
as reference in all the in vivo experiments. Restasis can
improve moderate and severe dry eye symptoms.3 Restasis is
an anionic castor oil-in-water emulsion stabilized by polysor-
bate 80.32,33 Even though the exact mechanism of CyA action
in the eye is not totally clear, this formulation is effective for
treating keratoconjunctivitis sicca. Some local side effects,
probably due to the castor oil, are reported, such as burning
and stinging sensations, conjunctival hyperemia, and eye
pain.12,34 The comfort for the patient can be increased by
the use of a novel micelle formulation that is well tolerat-
ed.13,16
Considering that nano-sized particles are in the same size
range as membrane receptors, proteins and other biomole-
cules, they have the ability to interact with cellular barriers,35
FIGURE 2. Corneal cells treated with the micelle formulation observed
by fluorescence widefield microscopy. (a, b) After 1 hour. (c, d) 24
hours of incubation (blue fluorescence ¼ nuclei stained with Hoechst
solution; yellow fluorescence ¼ DiO-loaded fluorescent micelles; red
fluorescence ¼ micelle prepared with labeled copolymer; green
fluorescence ¼ DiO).
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which is important because the cellular uptake is the first step
for the drug’s therapeutic action. For the treatment of ocular
surface diseases, such as dry eye, the ideal case would be the
uptake and the accumulation of the colloidal carriers
containing CyA into corneal cells, to form a drug depot from
which CyA would be released over time. To verify if the MPEG-
hexPLA micelles have this important carrier ability, corneal
primary cells were chosen because the corneal cells come in
contact with the formulation just after the instillation. Possibly,
this general evaluation could also apply to conjunctival cells,
which have similar characteristics and work as a barrier like the
corneal cells. The results show that the micelles were
internalized by the corneal cells and delivered the incorporated
model drug to the interior of the cells. Primary cells were
chosen also because they can provide further evidence of the
nontoxicity of the micelle formulation in vivo. In fact, primary
cells are more sensitive to toxic compounds than immortalized
cell lines. After 24 hours of incubation with the micelle
formulation, the cells were alive, meaning that these carriers
did not alter the cell structure or cause irreversible damage.
This provides additional evidence of the biocompatibility that
has already been demonstrated for this colloidal formulation.13
The CyA micelle formulation was evaluated in vivo in terms
of nonalteration of ocular surface equilibrium and its ability to
deliver CyA in therapeutic concentrations to lachrymal fluid
and surface ocular structures that are involved in dry eye
syndrome. The composition and the volume of tears are key
factors for a healthy ocular surface. Indeed, high film stability
provides a first line of protection to the eye and is essential to
avoid evaporation and to maintain coverage of the surface of
the eye during blinking.36 In dry eye, the characteristics of the
ocular surface are altered due to the reduction of tear
production and/or the abnormal evaporation of tear film.
Since none of the existing animal models seems to be
representative of the complexity and chronicity of this
multifactorial disease17 or to be suitable for assessing the
efficacy of a topical formulation, two classical tests for the
evaluation of the tear film were performed to investigate if the
micelle formulation would negatively interact with tears or the
ocular surface. A negative impact on any ocular surface
properties would cause modifications to the ocular surface,
such as reduced quantity and quality of the lipid tear layer,
altered tear composition, and ocular surface inflammation.37
Many tests of tear film stability are available to diagnose dry eye
syndrome. Among them, the Schirmer test is the simplest test
FIGURE 3. Orthogonal section of corneal cells treated with the micelle formulation observed by confocal fluorescence microscopy after 24 hours of
incubation (blue fluorescence¼ nuclei stained with Hoechst solution; yellow fluorescence¼DiO loaded fluorescent micelles; red fluorescence¼
micelle prepared with labeled copolymer; green fluorescence ¼ DiO).
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to assess the basal and reflexive tear production, and the
isotonicity measurement is a reproducible test that is the best
indicator of dry eye.1,2 Thus, in the present study, the Schirmer
test and the osmolarity measurement were chosen for the
evaluation of tear film and ocular surface problems after
instillation of the micelle formulation or Restasis.
The Schirmer test was performed with topical anaesthesia
to evaluate the basal tear secretion. The results show that the
micelle formulation did not alter the basal tear production. To
evaluate if the micelle formulation increased tear evaporation,
osmolarity measurements were also performed, as osmolarity is
an important parameter for tear electrolyte and sugar balance.
No alteration of tear osmolarity was observed after instillation.
Restasis yielded the same results in both tests. These results
imply that in healthy rabbit eyes, as used in this study, the
micelle formulation did not negatively affect the tear produc-
tion or the electrolyte concentration and had no influence on
the basal ocular conditions, similar to the reference product.
After topical instillation in the eye, two processes take
place: elimination from the ocular surface and absorption by
ocular tissues. The ability of the micelles to deliver CyA to
lachrymal fluid and the cornea, which are the ocular surface
structures involved in ophthalmic surface diseases, was
evaluated in rabbit and in rat eyes, respectively.
Concerning the kinetics of CyA in the lachrymal fluid, for
both tested formulations, there was a biphasic elimination
profile (Fig. 1a). The first elimination phase (Fig. 4b) was rapid,
lasting approximately 20 minutes; and the second elimination
phase was slower (Fig. 4c). The rapid elimination (typically 1–2
minutes)27,38 of an excess volume of instilled liquid from the
surface of the eye is due to naso-lachrymal drainage, tear
turnover, and protein binding.39 When the volume in the cul-de-
sac reverts to the basal value, the elimination of the drug from
the eye surface slows down with the normal tear turn-over (Fig.
4c), which corresponds to 7% per minute in rabbit eyes.40 The
precorneal kinetics indicated that after the first rapid elimina-
tion phase, 3 hours after the instillation, a CyA concentration of
327 6 262 ng/mL for the micelle formulation and of 142 6 70
ng/mL for Restasis were still present in the lachrymal fluid and
were consequently available for therapeutic action.
Since the micelle formulation yielded the same results as
Restasis in terms of alterations of ocular surface properties and
of the CyA concentration delivered to lachrymal fluid, this novel
colloidal formulation could be efficiently used to treat dry eye.
The absorption of the drug is regulated by the conjunctival
and corneal barriers, both limiting the drug diffusion. The
corneal absorption allows the drug to reach the corneal layers
and then the anterior chamber of the eye. The conjunctival
absorption diverts the majority of the drug to the systemic
circulation because it is a highly vascularized membrane. A
certain amount of the drug can be absorbed by the inner
tissues of the conjunctiva and reach the posterior segment of
the eye by the trans-scleral route.41 This evaluation showed the
ability of the micelle carriers to deliver CyA into corneal layers.
The results obtained for the CyA concentrations in tears and in
ocular tissues after topical instillation can be qualitatively
correlated even though these experiments were performed in
two different animal species because both are routinely used as
models for ocular investigations and both animals are used in
some dry eye models.17 The ocular distribution experiment in
rats showed another interesting feature of the micelle carriers.
The CyA concentration found in the corneas of animals treated
with the colloidal system was above the therapeutic CyA range
of concentrations (50–300 ng CyA/g tissue), with a value of 1540
6 400 ng CyA/g tissue. The CyA concentration in the corneas of
the rats treated with Restasis was below 2 ng/mL, correspond-
ing to the LOQ of the analytical method. The micelles can
deliver a high drug amount to the cornea, which becomes a
drug depot, releasing the drug over time. This effect is not
visible in a short period of time , since the CyA concentration
in tears was not significantly different after 3 hours for both
formulations. However, with the micelle formulation, the
number of instillations per day can be reduced by increasing
the patient’s compliance. Furthermore, recent studies by De
Paiva et al.42 suggested that with the dry eye disease, a primary
autoimmune reaction occurs not only in the conjunctiva but
also in the cornea. The cornea can be a suitable target for dry
eye treatment, whereby a suppression of the immune reaction
will significantly improve the protective function of the
corneal epithelial barrier.
FIGURE 4. CyA concentrations in lachrymal fluid of rabbit eyes after a
single instillation of either formulation. Values 6 SD. (a) CyA kinetics
over 180 minutes. (b) CyA kinetics over 20 minutes (first elimination
phase). (c) CyA kinetics between 30 and 180 minutes (second
elimination phase).
TABLE 1. CyA Pharmacokinetic Values in Lachrymal Fluid of Rabbits
after a Single Instillation of Micelle Formulation or Restasis (n¼ 6).
AUC (min*lg/mL) Cmax (lg/mL) Half-life (min)
Micelles 2339 6 1032 478 6 111 36 6 9
Restasis 2321 6 881 451 6 74 28 6 9
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Finally, it should be noted that after topical instillation, a
large amount of the applied drug can be systemically absorbed,
after which systemic side effects can occur. The CyA
concentrations in the bloodstream were quantified after
instillation of both formulations, and they were below 2 ng/
mL. No systemic absorption of the drug at a therapeutic level
was observed. Hence, the topical treatment with this micelle
formulation or Restasis can avoid systemic CyA side effects.
Both formulations showed no alteration of ocular surface
properties (Fig. 5) and precorneal kinetics parameters of CyA.
However, the nature of the formulation is an important factor
influencing CyA tolerance, availability, and elimination pro-
file.43 This study compared an aqueous clear micelle solution
to an oil-in-water opaque emulsion. In general, lipophilic
vehicles are poorly tolerated on the ocular surface, whereas
hydrophilic vehicles are better tolerated reducing the discom-
fort reported by patients. Furthermore, the hydrophobicity of
the excipients present in Restasis enhances the affinity of CyA
for this hydrophobic vehicle, reducing its affinity for the
hydrophilic tear layer, and then increasing its elimination from
the ocular surface. This is a probable explanation for the fact
that CyA was found only in the cornea of the rats treated with
micelle formulation and not in the rats instilled with Restasis.
In two previous studies,16,23 the ocular tolerance of Restasis
and micelle formulation was assessed by confocal laser
scanning ophthalmoscopy. This technique allowed the quan-
tification of the damage for the ocular surface caused by the
instilled formulation.44 Both formulations were considered to
be well tolerated with a percentage of the injured ocular
surface of less than 20%.45 However, the damaged ocular
surface was 18.00 6 6.82% in the case of Restasis compared to
5.63 6 2.82% for the micelle formulation. It is expected for a
formulation that is less well tolerated, that the activation of
protective mechanisms of the eye can increase the drug
elimination and decrease the drug absorption. Thus, the
presented novel formulation shows important advantages in
terms of ocular tolerance and corneal penetration compared to
the commercial product.
SUMMARY AND CONCLUSIONS
The aim of this study was the in vitro and in vivo evaluation of
a novel CyA topical formulation for dry eye treatment.
This study showed the ability of MPEG-hexPLA micelles to
interact with corneal primary cells and release the incorporat-
ed drug model inside the target cells. No influence on the
primary cell viability was observed. The CyA micelle formula-
tion did not affect the surface ocular properties when topically
instilled in rabbit eyes, which mirrored the results of the
commercial CyA emulsion used as a reference. These in vitro
and in vivo surface evaluations confirm the biocompatibility of
the novel micelle formulation.
The CyA concentration found in lachrymal fluid was compa-
rable between the two formulations and showed that after a first
elimination phase, CyA was still present in tears 3 hours after
instillation. The CyA micelle formulation was able to efficiently
deliver CyA into the cornea, reaching therapeutic concentrations
after a protocol of two instillations per day for 5 days. The MPEG-
hexPLA micelle formulation was able to provide a selective
delivery of CyA into the cornea, avoiding systemic absorption and
without compromising the ocular surface stability. Furthermore,
due to its patient-friendly characteristics, such as transparency,
ocular tolerance and biocompatibility, the micelle formulation
could be efficiently applied topically without reducing the
patient’s compliance. This new colloidal formulation could be
efficiently applied to humans for the treatment of immune-
mediated ocular surface diseases for which administration of CyA
is required. In particular, this novel CyA formulation is suitable for
dry eye treatment.
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